In preclinical studies, SRT2104 demonstrated a lowering of fasting blood glucose and insulin, reduced weight gain, increased energy expenditure, improved exercise tolerance and improved insulin sensitivity in the diet-induced obesity model of Type 2 Diabetes. (See Publications and Meetings)
SRT2104 was Sirtris' first NCE to enter human trials. The Phase I program in healthy volunteers demonstrated favorable safety and tolerability. (see Scientific Publications). The Phase I program was followed by a small translational medicine study in acute inflammation as well as two clinical studies in Type 2 Diabetes. SRT2104 continues development in separate Phase II trials in psoriasis, ulcerative colitis and vascular disorders.